schliessen

Filtern

 

Bibliotheken

Cover Image

Clustering of Metabolic Abnormalities Among Obese Patients and Mortality After Percutaneous Coronary Intervention

Although current literature demonstrates metabolic abnormalities are associated with mortality, obese patients who tend to have more metabolic abnormalities paradoxically have lower overall mortality rates compared to their normal-weight counterparts. In this study, we examined the prevalence of met... Full description

Journal Title: The American journal of cardiology 2011, Vol.107 (10), p.1415-1420
Main Author: Bashey, Sameer, MD
Other Authors: Muntner, Paul, PhD , Kini, Annapoorna S., MD , Esquitin, Ricardo, MD , Razzouk, Louai, MD , Mathewkutty, Shiny, MD , Wildman, Rachel P., PhD , Carson, April P., PhD , Kim, Michael C., MD , Moreno, Pedro R., MD , Sharma, Samin K., MD , Farkouh, Michael E., MD, MSc
Format: Electronic Article Electronic Article
Language: English
Subjects:
Abridged Index Medicus
Aged
Angioplasty, Balloon, Coronary
Biological and medical sciences
Blood Glucose - analysis
Body Mass Index
C-Reactive Protein - analysis
Cardiac patients
Cardiology
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Cholesterol
Cholesterol, HDL - blood
Cluster Analysis
Dextrose
Diabetes
Diseases of the cardiovascular system
Female
Glucose
Humans
Hypertension
Hypertension - complications
Male
Medical sciences
Metabolic diseases
Metabolism
Mortality
Obesity
Obesity - complications
Obesity - metabolism
Obesity - mortality
Patient outcomes
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Transluminal angioplasty
Triglycerides
Triglycerides - blood
Publisher: New York, NY: Elsevier Inc
ID: ISSN: 0002-9149
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_864964782
title: Clustering of Metabolic Abnormalities Among Obese Patients and Mortality After Percutaneous Coronary Intervention
format: Article
creator:
  • Bashey, Sameer, MD
  • Muntner, Paul, PhD
  • Kini, Annapoorna S., MD
  • Esquitin, Ricardo, MD
  • Razzouk, Louai, MD
  • Mathewkutty, Shiny, MD
  • Wildman, Rachel P., PhD
  • Carson, April P., PhD
  • Kim, Michael C., MD
  • Moreno, Pedro R., MD
  • Sharma, Samin K., MD
  • Farkouh, Michael E., MD, MSc
subjects:
  • Abridged Index Medicus
  • Aged
  • Angioplasty, Balloon, Coronary
  • Biological and medical sciences
  • Blood Glucose - analysis
  • Body Mass Index
  • C-Reactive Protein - analysis
  • Cardiac patients
  • Cardiology
  • Cardiology. Vascular system
  • Cardiovascular
  • Cardiovascular disease
  • Cholesterol
  • Cholesterol, HDL - blood
  • Cluster Analysis
  • Dextrose
  • Diabetes
  • Diseases of the cardiovascular system
  • Female
  • Glucose
  • Humans
  • Hypertension
  • Hypertension - complications
  • Male
  • Medical sciences
  • Metabolic diseases
  • Metabolism
  • Mortality
  • Obesity
  • Obesity - complications
  • Obesity - metabolism
  • Obesity - mortality
  • Patient outcomes
  • Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
  • Transluminal angioplasty
  • Triglycerides
  • Triglycerides - blood
ispartof: The American journal of cardiology, 2011, Vol.107 (10), p.1415-1420
description: Although current literature demonstrates metabolic abnormalities are associated with mortality, obese patients who tend to have more metabolic abnormalities paradoxically have lower overall mortality rates compared to their normal-weight counterparts. In this study, we examined the prevalence of metabolic abnormality clustering and its relation to mortality in obese and normal-weight patients after percutaneous coronary intervention (PCI). Patients (n = 9,673) undergoing elective PCI from October 2003 through December 2006 at a single urban hospital were categorized by body mass index (BMI) levels of 18.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9, and ≥35 kg/m2 and by number of metabolic abnormalities possessed (hypertension, impaired fasting glucose/diabetes, triglycerides ≥150 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, and C-reactive protein ≥2.0 mg/L). All-cause mortality was assessed through June 30, 2007. Mean age of patients was 65.9 years and 66% were men. Prevalences of 4 or 5 metabolic abnormalities were 12%, 18%, 24%, and 31% in patients with BMI levels of 18.5 to 24.9, 25.0 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In patients with BMI of 30.0 to 34.9 kg/m2 , hazard ratios (95% confidence intervals) for mortality associated with 2, 3, and 4 to 5 metabolic abnormalities versus 0 to 1 metabolic abnormality were 1.31 (0.79 to 2.17), 1.42 (0.83 to 2.43), and 2.39 (1.24 to 4.59), respectively. Analogous hazard ratios for patients with BMI ≥35 kg/m2 were 1.94 (0.90 to 4.20), 1.44 (0.63 to 3.28), and 2.17 (0.91 to 5.18). All-cause mortality rates per 1,000 person-years were 55.5, 33.7, 28.3, and 33.8 in patients with BMI levels of 18.5 to 24.9, 25 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In conclusion, BMI levels of 25.0 to 29.9 and 30 to 34.9 kg/m2 were associated with lower all-cause mortality after PCI. However, an increased number of metabolic abnormalities translated into increased all-cause mortality.
language: eng
source:
identifier: ISSN: 0002-9149
fulltext: no_fulltext
issn:
  • 0002-9149
  • 1879-1913
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.2808015
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_864964782
sourceformatXML
sourcesystemPC
galeidA257571394
sourcerecordidA257571394
originalsourceidFETCH-LOGICAL-c505t-ced9a11e94db78a1a507285f5f536ef83a915003cc857c3f2a41f604446630be0
addsrcrecordideNqFkl1rFDEUhgdR7Lb6E5RBEK92PclM5gOhsixVCy0tqNchkzlTss4kbZIp7L_3hF0r7E1JIF_Pe_KSN1n2jsGKAas-b1dq2mrl-xUHxlaQOn-RLVhTt0vWsuJltgAAvmxZ2Z5kpyFsacmYqF5nJ5yVHECUi-xhM84hojf2LndDfo1RdW40Ol931vlJjSYaDPl6cgTcdBgwv1W0ZWPIle3za-djgnb5eqAy-S16PUdl0c0h3zjvrPK7_NLS2SOJjLNvsleDGgO-PYxn2e9vF782P5ZXN98vN-urpRYg4lJj3yrGsC37rm4UUwJq3oiBWlHh0BSqZQKg0LoRtS4Grko2VFCWZVUV0CGcZZ_2de-9e5gxRDmZoHEc9-ZkU5VtVdYNJ_LDEbl1s7dkjqBacLoWCFrtoTs1ojR2cNErTa3HyWhncTC0v-aiFjUr2pIEYi_Q3oXgcZD33kz0GpKBTBHKrTxEKFOEElJPbt4f3MzdhP2T6l9mBHw8ACpoNQ5eWW3Cfy5hULfEfTkyoE1UKQJybsZnbXzdq5EyejToZdAUO8ViPOooe2eerXB-VEGPxhqy_Ad3GJ7emMnAJcif6bemz8pYmjQAfwFlMuS_
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid867522850
display
typearticle
titleClustering of Metabolic Abnormalities Among Obese Patients and Mortality After Percutaneous Coronary Intervention
creatorBashey, Sameer, MD ; Muntner, Paul, PhD ; Kini, Annapoorna S., MD ; Esquitin, Ricardo, MD ; Razzouk, Louai, MD ; Mathewkutty, Shiny, MD ; Wildman, Rachel P., PhD ; Carson, April P., PhD ; Kim, Michael C., MD ; Moreno, Pedro R., MD ; Sharma, Samin K., MD ; Farkouh, Michael E., MD, MSc
creatorcontribBashey, Sameer, MD ; Muntner, Paul, PhD ; Kini, Annapoorna S., MD ; Esquitin, Ricardo, MD ; Razzouk, Louai, MD ; Mathewkutty, Shiny, MD ; Wildman, Rachel P., PhD ; Carson, April P., PhD ; Kim, Michael C., MD ; Moreno, Pedro R., MD ; Sharma, Samin K., MD ; Farkouh, Michael E., MD, MSc
descriptionAlthough current literature demonstrates metabolic abnormalities are associated with mortality, obese patients who tend to have more metabolic abnormalities paradoxically have lower overall mortality rates compared to their normal-weight counterparts. In this study, we examined the prevalence of metabolic abnormality clustering and its relation to mortality in obese and normal-weight patients after percutaneous coronary intervention (PCI). Patients (n = 9,673) undergoing elective PCI from October 2003 through December 2006 at a single urban hospital were categorized by body mass index (BMI) levels of 18.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9, and ≥35 kg/m2 and by number of metabolic abnormalities possessed (hypertension, impaired fasting glucose/diabetes, triglycerides ≥150 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, and C-reactive protein ≥2.0 mg/L). All-cause mortality was assessed through June 30, 2007. Mean age of patients was 65.9 years and 66% were men. Prevalences of 4 or 5 metabolic abnormalities were 12%, 18%, 24%, and 31% in patients with BMI levels of 18.5 to 24.9, 25.0 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In patients with BMI of 30.0 to 34.9 kg/m2 , hazard ratios (95% confidence intervals) for mortality associated with 2, 3, and 4 to 5 metabolic abnormalities versus 0 to 1 metabolic abnormality were 1.31 (0.79 to 2.17), 1.42 (0.83 to 2.43), and 2.39 (1.24 to 4.59), respectively. Analogous hazard ratios for patients with BMI ≥35 kg/m2 were 1.94 (0.90 to 4.20), 1.44 (0.63 to 3.28), and 2.17 (0.91 to 5.18). All-cause mortality rates per 1,000 person-years were 55.5, 33.7, 28.3, and 33.8 in patients with BMI levels of 18.5 to 24.9, 25 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In conclusion, BMI levels of 25.0 to 29.9 and 30 to 34.9 kg/m2 were associated with lower all-cause mortality after PCI. However, an increased number of metabolic abnormalities translated into increased all-cause mortality.
identifier
0ISSN: 0002-9149
1EISSN: 1879-1913
2DOI: 10.1016/j.amjcard.2011.01.012
3PMID: 21420054
4CODEN: AJCDAG
languageeng
publisherNew York, NY: Elsevier Inc
subjectAbridged Index Medicus ; Aged ; Angioplasty, Balloon, Coronary ; Biological and medical sciences ; Blood Glucose - analysis ; Body Mass Index ; C-Reactive Protein - analysis ; Cardiac patients ; Cardiology ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular disease ; Cholesterol ; Cholesterol, HDL - blood ; Cluster Analysis ; Dextrose ; Diabetes ; Diseases of the cardiovascular system ; Female ; Glucose ; Humans ; Hypertension ; Hypertension - complications ; Male ; Medical sciences ; Metabolic diseases ; Metabolism ; Mortality ; Obesity ; Obesity - complications ; Obesity - metabolism ; Obesity - mortality ; Patient outcomes ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Transluminal angioplasty ; Triglycerides ; Triglycerides - blood
ispartofThe American journal of cardiology, 2011, Vol.107 (10), p.1415-1420
rights
0Elsevier Inc.
12011 Elsevier Inc.
22015 INIST-CNRS
3Copyright © 2011 Elsevier Inc. All rights reserved.
4COPYRIGHT 2011 Elsevier B.V.
5Copyright Elsevier Sequoia S.A. May 15, 2011
lds50peer_reviewed
citedbyFETCH-LOGICAL-c505t-ced9a11e94db78a1a507285f5f536ef83a915003cc857c3f2a41f604446630be0
citesFETCH-LOGICAL-c505t-ced9a11e94db78a1a507285f5f536ef83a915003cc857c3f2a41f604446630be0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24200079$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21420054$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Bashey, Sameer, MD
1Muntner, Paul, PhD
2Kini, Annapoorna S., MD
3Esquitin, Ricardo, MD
4Razzouk, Louai, MD
5Mathewkutty, Shiny, MD
6Wildman, Rachel P., PhD
7Carson, April P., PhD
8Kim, Michael C., MD
9Moreno, Pedro R., MD
10Sharma, Samin K., MD
11Farkouh, Michael E., MD, MSc
title
0Clustering of Metabolic Abnormalities Among Obese Patients and Mortality After Percutaneous Coronary Intervention
1The American journal of cardiology
addtitleAm J Cardiol
descriptionAlthough current literature demonstrates metabolic abnormalities are associated with mortality, obese patients who tend to have more metabolic abnormalities paradoxically have lower overall mortality rates compared to their normal-weight counterparts. In this study, we examined the prevalence of metabolic abnormality clustering and its relation to mortality in obese and normal-weight patients after percutaneous coronary intervention (PCI). Patients (n = 9,673) undergoing elective PCI from October 2003 through December 2006 at a single urban hospital were categorized by body mass index (BMI) levels of 18.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9, and ≥35 kg/m2 and by number of metabolic abnormalities possessed (hypertension, impaired fasting glucose/diabetes, triglycerides ≥150 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, and C-reactive protein ≥2.0 mg/L). All-cause mortality was assessed through June 30, 2007. Mean age of patients was 65.9 years and 66% were men. Prevalences of 4 or 5 metabolic abnormalities were 12%, 18%, 24%, and 31% in patients with BMI levels of 18.5 to 24.9, 25.0 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In patients with BMI of 30.0 to 34.9 kg/m2 , hazard ratios (95% confidence intervals) for mortality associated with 2, 3, and 4 to 5 metabolic abnormalities versus 0 to 1 metabolic abnormality were 1.31 (0.79 to 2.17), 1.42 (0.83 to 2.43), and 2.39 (1.24 to 4.59), respectively. Analogous hazard ratios for patients with BMI ≥35 kg/m2 were 1.94 (0.90 to 4.20), 1.44 (0.63 to 3.28), and 2.17 (0.91 to 5.18). All-cause mortality rates per 1,000 person-years were 55.5, 33.7, 28.3, and 33.8 in patients with BMI levels of 18.5 to 24.9, 25 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In conclusion, BMI levels of 25.0 to 29.9 and 30 to 34.9 kg/m2 were associated with lower all-cause mortality after PCI. However, an increased number of metabolic abnormalities translated into increased all-cause mortality.
subject
0Abridged Index Medicus
1Aged
2Angioplasty, Balloon, Coronary
3Biological and medical sciences
4Blood Glucose - analysis
5Body Mass Index
6C-Reactive Protein - analysis
7Cardiac patients
8Cardiology
9Cardiology. Vascular system
10Cardiovascular
11Cardiovascular disease
12Cholesterol
13Cholesterol, HDL - blood
14Cluster Analysis
15Dextrose
16Diabetes
17Diseases of the cardiovascular system
18Female
19Glucose
20Humans
21Hypertension
22Hypertension - complications
23Male
24Medical sciences
25Metabolic diseases
26Metabolism
27Mortality
28Obesity
29Obesity - complications
30Obesity - metabolism
31Obesity - mortality
32Patient outcomes
33Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
34Transluminal angioplasty
35Triglycerides
36Triglycerides - blood
issn
00002-9149
11879-1913
fulltextfalse
rsrctypearticle
creationdate2011
recordtypearticle
recordideNqFkl1rFDEUhgdR7Lb6E5RBEK92PclM5gOhsixVCy0tqNchkzlTss4kbZIp7L_3hF0r7E1JIF_Pe_KSN1n2jsGKAas-b1dq2mrl-xUHxlaQOn-RLVhTt0vWsuJltgAAvmxZ2Z5kpyFsacmYqF5nJ5yVHECUi-xhM84hojf2LndDfo1RdW40Ol931vlJjSYaDPl6cgTcdBgwv1W0ZWPIle3za-djgnb5eqAy-S16PUdl0c0h3zjvrPK7_NLS2SOJjLNvsleDGgO-PYxn2e9vF782P5ZXN98vN-urpRYg4lJj3yrGsC37rm4UUwJq3oiBWlHh0BSqZQKg0LoRtS4Grko2VFCWZVUV0CGcZZ_2de-9e5gxRDmZoHEc9-ZkU5VtVdYNJ_LDEbl1s7dkjqBacLoWCFrtoTs1ojR2cNErTa3HyWhncTC0v-aiFjUr2pIEYi_Q3oXgcZD33kz0GpKBTBHKrTxEKFOEElJPbt4f3MzdhP2T6l9mBHw8ACpoNQ5eWW3Cfy5hULfEfTkyoE1UKQJybsZnbXzdq5EyejToZdAUO8ViPOooe2eerXB-VEGPxhqy_Ad3GJ7emMnAJcif6bemz8pYmjQAfwFlMuS_
startdate2011
enddate2011
creator
0Bashey, Sameer, MD
1Muntner, Paul, PhD
2Kini, Annapoorna S., MD
3Esquitin, Ricardo, MD
4Razzouk, Louai, MD
5Mathewkutty, Shiny, MD
6Wildman, Rachel P., PhD
7Carson, April P., PhD
8Kim, Michael C., MD
9Moreno, Pedro R., MD
10Sharma, Samin K., MD
11Farkouh, Michael E., MD, MSc
general
0Elsevier Inc
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
107QO
117TS
128FD
13FR3
14K9.
15P64
167X8
sort
creationdate2011
titleClustering of Metabolic Abnormalities Among Obese Patients and Mortality After Percutaneous Coronary Intervention
authorBashey, Sameer, MD ; Muntner, Paul, PhD ; Kini, Annapoorna S., MD ; Esquitin, Ricardo, MD ; Razzouk, Louai, MD ; Mathewkutty, Shiny, MD ; Wildman, Rachel P., PhD ; Carson, April P., PhD ; Kim, Michael C., MD ; Moreno, Pedro R., MD ; Sharma, Samin K., MD ; Farkouh, Michael E., MD, MSc
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c505t-ced9a11e94db78a1a507285f5f536ef83a915003cc857c3f2a41f604446630be0
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Abridged Index Medicus
1Aged
2Angioplasty, Balloon, Coronary
3Biological and medical sciences
4Blood Glucose - analysis
5Body Mass Index
6C-Reactive Protein - analysis
7Cardiac patients
8Cardiology
9Cardiology. Vascular system
10Cardiovascular
11Cardiovascular disease
12Cholesterol
13Cholesterol, HDL - blood
14Cluster Analysis
15Dextrose
16Diabetes
17Diseases of the cardiovascular system
18Female
19Glucose
20Humans
21Hypertension
22Hypertension - complications
23Male
24Medical sciences
25Metabolic diseases
26Metabolism
27Mortality
28Obesity
29Obesity - complications
30Obesity - metabolism
31Obesity - mortality
32Patient outcomes
33Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
34Transluminal angioplasty
35Triglycerides
36Triglycerides - blood
toplevelpeer_reviewed
creatorcontrib
0Bashey, Sameer, MD
1Muntner, Paul, PhD
2Kini, Annapoorna S., MD
3Esquitin, Ricardo, MD
4Razzouk, Louai, MD
5Mathewkutty, Shiny, MD
6Wildman, Rachel P., PhD
7Carson, April P., PhD
8Kim, Michael C., MD
9Moreno, Pedro R., MD
10Sharma, Samin K., MD
11Farkouh, Michael E., MD, MSc
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9Biotechnology Research Abstracts
10Physical Education Index
11Technology Research Database
12Engineering Research Database
13ProQuest Health & Medical Complete (Alumni)
14Biotechnology and BioEngineering Abstracts
15MEDLINE - Academic
jtitleThe American journal of cardiology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Bashey, Sameer, MD
1Muntner, Paul, PhD
2Kini, Annapoorna S., MD
3Esquitin, Ricardo, MD
4Razzouk, Louai, MD
5Mathewkutty, Shiny, MD
6Wildman, Rachel P., PhD
7Carson, April P., PhD
8Kim, Michael C., MD
9Moreno, Pedro R., MD
10Sharma, Samin K., MD
11Farkouh, Michael E., MD, MSc
formatjournal
genrearticle
ristypeJOUR
atitleClustering of Metabolic Abnormalities Among Obese Patients and Mortality After Percutaneous Coronary Intervention
jtitleThe American journal of cardiology
addtitleAm J Cardiol
date2011
risdate2011
volume107
issue10
spage1415
epage1420
pages1415-1420
issn0002-9149
eissn1879-1913
codenAJCDAG
abstractAlthough current literature demonstrates metabolic abnormalities are associated with mortality, obese patients who tend to have more metabolic abnormalities paradoxically have lower overall mortality rates compared to their normal-weight counterparts. In this study, we examined the prevalence of metabolic abnormality clustering and its relation to mortality in obese and normal-weight patients after percutaneous coronary intervention (PCI). Patients (n = 9,673) undergoing elective PCI from October 2003 through December 2006 at a single urban hospital were categorized by body mass index (BMI) levels of 18.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9, and ≥35 kg/m2 and by number of metabolic abnormalities possessed (hypertension, impaired fasting glucose/diabetes, triglycerides ≥150 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, and C-reactive protein ≥2.0 mg/L). All-cause mortality was assessed through June 30, 2007. Mean age of patients was 65.9 years and 66% were men. Prevalences of 4 or 5 metabolic abnormalities were 12%, 18%, 24%, and 31% in patients with BMI levels of 18.5 to 24.9, 25.0 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In patients with BMI of 30.0 to 34.9 kg/m2 , hazard ratios (95% confidence intervals) for mortality associated with 2, 3, and 4 to 5 metabolic abnormalities versus 0 to 1 metabolic abnormality were 1.31 (0.79 to 2.17), 1.42 (0.83 to 2.43), and 2.39 (1.24 to 4.59), respectively. Analogous hazard ratios for patients with BMI ≥35 kg/m2 were 1.94 (0.90 to 4.20), 1.44 (0.63 to 3.28), and 2.17 (0.91 to 5.18). All-cause mortality rates per 1,000 person-years were 55.5, 33.7, 28.3, and 33.8 in patients with BMI levels of 18.5 to 24.9, 25 to 29.9, 30 to 34.9, and ≥35 kg/m2 , respectively. In conclusion, BMI levels of 25.0 to 29.9 and 30 to 34.9 kg/m2 were associated with lower all-cause mortality after PCI. However, an increased number of metabolic abnormalities translated into increased all-cause mortality.
copNew York, NY
pubElsevier Inc
pmid21420054
doi10.1016/j.amjcard.2011.01.012